BiVACOR’s Total Artificial Heart (TAH) has the potential to revolutionise the treatment of end-stage heart failure. It offers the potential of a permanent solution for patients suffering from this debilitating condition, providing them with full cardiac support and the ability to live a more normal life.
The TAH’s innovative combination of magnetic levitation technology and artificial intelligence allows it to replicate the natural pumping action of a healthy heart, improving blood flow and reducing the symptoms of heart failure. It also aims to bridge the patient to transplant, potentially extending their life.
This device represents a significant step forward in the field of medical technology, offering hope to patients with end-stage heart failure and their families, and has the potential to change the lives of thousands of people in need of a heart transplant.
OneVentures are a unique, one of a kind investor in the venture capital world.
They put tremendous faith in their portfolio company’s teams to deliver results, and are always on hand to provide pointed advice or step in to fill organisational gaps. BiVACOR has fortunately been part of the OneVentures family for nearly 4 years now, and their unyielding support has allowed our organisation to pursue our dream of developing a practical replacement to the failing human heart. Without the OneVentures team, we would not be where we are today!